Leukodystrophies in idiopathic adult-onset ataxia: Frequency and phenotype in 105 patients

Authors

  • Jennifer Müller vom Hagen MD,

    1. Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
    2. German Research Centre for Neurodegenerative Diseases (DZNE), Tübingen, Germany
    Search for more papers by this author
  • Matthis Synofzik MD,

    1. Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
    2. German Research Centre for Neurodegenerative Diseases (DZNE), Tübingen, Germany
    Search for more papers by this author
  • Julia Schicks MD,

    1. Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
    2. German Research Centre for Neurodegenerative Diseases (DZNE), Tübingen, Germany
    Search for more papers by this author
  • Ingeborg Krägeloh-Mann MD,

    1. German Research Centre for Neurodegenerative Diseases (DZNE), Tübingen, Germany
    2. Department of Neuropaediatrics, University of Tübingen, Tübingen, Germany
    Search for more papers by this author
  • Ludger Schöls MD

    Corresponding author
    1. Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
    2. German Research Centre for Neurodegenerative Diseases (DZNE), Tübingen, Germany
    Search for more papers by this author

  • Relevant conflicts of interest/financial disclosures: Nothing to report.

  • Full financial disclosures and author roles may be found in the online version of this article.

  • Dr. J. Müller vom Hagen received a travel grant by Actelion Pharmaceuticals.

  • Dr. Synofzik received a research grant by the Volkswagen Foundation, a travel grant by the Movement Disorders Society, and honoria from Fresenius Kabi and Actelion Pharmaceuticals.

  • Dr. Schicks received a travel grant by the Movement Disorder Society and a research grant by the fortune-Programm, University of Tuebingen (1890-0-0).

  • Dr. Schöls received research grants of the Deutsche Forschungsgemeinschaft (SCHO754/4-1 and SCHO754/5-1), grants of the German Research Council (BMBF) to Leukonet (01GM0644) and mitoNET (01GM0864) and E-RARE grants to EUROSPA (01GM0807) and RISCA (01GM0820). He further received funding from the HSP-Selbsthilfegruppe Deutschland eV.

  • Dr. Krägeloh-Mann was member of the scientific board of the biopharmaceutical company ZYMENEX for a clinical trial I/II-study for enzyme replacement in MLD in 2007; and is currently member of the scientific board of the biopharmaceutical company SHIRE for a world-wide clinical trial I/II-study for intrathecal enzyme replacement in MLD. This did not imply any involvement, nor funding in the present study.

No abstract is available for this article.

Ancillary